Seasonal Influenza is an indication for drug development with over 60 pipeline drugs currently active. According to GlobalData, preregistered drugs for Seasonal Influenza have a 50% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Seasonal Influenza compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Seasonal Influenza overview
Seasonal influenza, commonly referred to as “the flu”, is a contagious respiratory illness caused by influenza viruses. It typically occurs in outbreaks during the fall and winter months, peaking between December and February in the Northern Hemisphere. The flu can cause mild to severe illness and, in some cases, can lead to hospitalization or even death, especially among vulnerable populations. Symptoms of the flu include fever, cough, sore throat, runny or stuffy nose, body aches, fatigue, headaches, and sometimes vomiting or diarrhea, especially in children. The flu virus spreads primarily through respiratory droplets when an infected person coughs, sneezes, or talks. It can also spread by touching a surface or object contaminated with the virus and then touching the mouth, nose, or eyes.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Seasonal Influenza, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.